Methyldopa Crescent Pharma (Methyldopa)

Methyldopa is employed in the management of blood‑pressure disorders that involve sympathetic overactivity.

• Hypertension: lowers systolic and diastolic pressure in adults with primary hypertension.
• Gestational hypertension: controls elevated blood pressure during pregnancy.
• Essential hypertension: provides long‑term blood‑pressure control in patients with chronic hypertension.

• Methyldopa is converted in the brain to alpha‑methylnorepinephrine, which stimulates central alpha‑2 adrenergic receptors. Activation of these receptors reduces sympathetic nervous system outflow, decreasing peripheral vascular resistance and cardiac output, thereby lowering arterial blood pressure.

Methyldopa may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Drowsiness: feeling unusually sleepy or fatigued.
• Dry mouth: reduced salivation leading to oral discomfort.
• Headache: mild to moderate cranial pain.
• Dizziness: sensation of light‑headedness, especially on standing.
• Weakness: generalized lack of strength.
• Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects

• Hemolytic anemia: destruction of red blood cells requiring medical attention.
• Liver dysfunction: elevated liver enzymes or hepatitis.
• Severe hypotension: dangerously low blood pressure.
• Lupus‑like syndrome: autoimmune symptoms resembling systemic lupus.
• Agranulocytosis: marked reduction in white blood cells.

When prescribing Methyldopa, clinicians should consider several safety measures.

• Blood pressure monitoring: adjust dose based on regular measurements.
• Liver function assessment: perform baseline and periodic liver tests.
• Hemolysis surveillance: watch for signs of anemia such as fatigue or jaundice.
• Depression evaluation: monitor mood changes, as central activity may affect mental health.
• Discontinuation caution: avoid abrupt stop to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methyldopa can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension.
• Other central alpha‑2 agonists (e.g., clonidine): additive hypotensive effect.
• Other antihypertensives (beta‑blockers, calcium channel blockers): excessive blood‑pressure lowering.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive response.
• Insulin or oral hypoglycemics: can mask hypoglycemia symptoms.